Alzheon to Present at the 2015 Ladenburg Thalmann Healthcare Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced the Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer, will present at the 2015 Ladenburg Thalmann Healthcare Conference at the Sofitel on September 29, 2015 at 9:00 a.m. Eastern Time in New York, NY.

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders. www.alzheon.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150929005943/en/

Media Contact:
MacDougall Biomedical Communications
Douglas MacDougall, 781-235-3060
[email protected]

Source: Alzheon Inc.

You May Also Be Interested In

• EquipmentShare.com Inc. Notice of September 21, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• Madrona Announces the 2026 Intelligent Applications 40, Recognizing the World's Leading Private AI Companies
• Human Risk Management Leaders from Reveal Risk, Bayer, and Labcorp to Speak at HRMCon 2026